ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 2126

Analysis of the Evolution of Bone Mineral Density in the Spanish Population: Results of the OsteoSER Study
Abstract Number: 2127

Relationship Between Serum Uric Acid and Trabecular Bone Score (TBS) in Healthy Population
Abstract Number: 2128

Trabecular Bone Score Curve from a Qatari Population, Data from Qatar Biobank
Abstract Number: 2129

Fracture Risk Assessment Tool (FRAX®) Scores Predict Mortality in Community-Dwelling Elderlies
Abstract Number: 2130

Post-fracture Survival for Rheumatoid Arthritis Patients Is Not Improving
Abstract Number: 2131

Role of LECT2 in the Regulation of Bone Metabolism In Vitro and In Vivo
Abstract Number: 2132

A Quality Improvement Initiative to Increase Osteoporosis Screening in Internal Medicine Resident Led Primary Care Clinics
Abstract Number: 2133

Unveiling the Association Between Low-Density Lipoprotein Cholesterol Lowering and Fracture Risk Among Patients with Hyperlipidaemia in a Population-Based Cohort Study: The Lower, the Better
Abstract Number: 2134

PEX5 Acts as a Negative Regulator of RANKL-induced Osteoclastogenesis In Vitro and Inflammatory Calvarial Bone Destruction In Vivo
Abstract Number: 2135

Disability, Functional Limitation, and Use of Anti-fracture Drug Therapies in a Cohort of 3651 U.S. Adults with Osteogenesis Imperfecta
Abstract Number: 2136

Distal Radius Correlation with Femur and Lumbar Spine T-scores: A Comprehensive Analysis
Abstract Number: 2137

Fractures Post Lung Transplant: A Retrospective Cohort Study Conducted at an International Transplant Center
Abstract Number: 2138

DXA-derived 3D Parameters of the Hip Discriminate Prevalent Fragility Fractures in Individuals with Axial Spondyloarthritis
Abstract Number: 2139

Generation of a Human 3D Bone Model to Mimic Glucocorticoid- induced Osteoporosis In Vitro
Abstract Number: 2140

Frailty Is Associated with Lower Bone Mineral Density in US Veterans with Rheumatoid Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].